humans (Midasch et al., 2007; Monroy et al., 2008) . Previous epidemiological studies have 15 shown a positive or negative association between perfluorooctane sulfonic acid (PFOS) and 16 perfluorooctanoic acid (PFOA) and levels of cord blood immunoglobulin (Ig) E (Okada et 17 al., 2012; Wang IJ et al., 2011) . Moreover, these studies have reported no association 18 between prenatal PFOS, PFOA, or perfluorononanoic acid (PFNA) exposure and allergic 19 and infectious diseases as health outcomes in children (Fei et al., 2010; Okada et al., 2012; 20 Wang IJ et al., 2011) . In the C8 Health Project, which was a cross-sectional, immune 1 biomarker study that investigated residents in the vicinity of a PFOA plant, IgA, IgE, and 2 C-reactive protein levels significantly decreased with increasing PFOA levels in blood 3 samples (Fletcher et al., 2009 ). population (Olsen et al., 2012; Sundström et al., 2011; Wang M et al., 2011) . In contrast,
11
concentrations of PFNA and perfluorodecanoic acid (PFDA), which are long-chain 12 perfluorinated carboxylic acids (PFCAs), are increasing in the general human population 13 (Wang M et al., 2011) . However, the effects of prenatal exposure to other PFAAs, 14 particularly PFCAs, which generally have longer chains than PFOA with a carbon chain 15 length of eight (e.g., PFDA, perfluoroundecanoic acid (PFUnDA), perfluorododecanoic 16 acid (PFDoDA), and perfluorotridecanoic acid (PFTrDA)), have not been characterized.
17
PFCAs with chains longer than those of PFOA have high bioconcentration factors, 18 suggesting that they are environmentally persistent (Martin et al., 2003) . Furthermore, 19 between 2003 and 2011, we reported increased PFNA and PFDA in maternal plasma levels 20 in Japanese, whereas levels of PFOS and PFOA decreased (Okada et al., 2013 malformations that became apparent from the follow-up questionnaire at 12 months (n = 10 17) and those whose maternal blood samples were taken before 26 weeks of gestation (n = 11 15) because the time of blood sampling during pregnancy may have affected concentrations 12 due to increased maternal blood volume during gestation. Thus, a final total of 2,063 study 13 participants met the specific exclusion and inclusion criteria for this study (Fig. 1) PFUnDA, PFDoDA, and PFTrDA (>90%), whereas PFHxS was detected in 81.9% of 9 samples. PFHxA, PFHpA, and PFTeDA were detected in <50% of samples, and therefore, we 10 did not include these compounds in the statistical analysis. PFOS was found at the highest 11 median concentration (5.02 ng/mL), followed by PFOA (2.01 ng/mL), PFUnDA (1.40 12 ng/mL), and PFNA (1.15 ng/mL). We excluded a participant with an exceptionally high 13 maternal PFOS concentration (464.8 ng/mL) as an outlier; this value was 93 times higher 14 than the median concentration in our study and 51 times higher than the median concentration 15 in the highest PFOS concentration area in Japan (Harada et al., 2010) . Therefore, data from a 16 final total of 2,062 participants were included in this study.
The incidences of infant allergic diseases during the first 24 months were determined 18 for our study group ( in the present study were higher than those seen in many countries but lower than levels 
Table 4
Odds ratio (95% CI) between PFAA concentrations in maternal plasma and total allergic diseases during the first 24 months in the Hokkaido Study on Environment and Children's Health, Japan, 2003-2009 (n = 2,062) . Table 5 Odds ratio (95% CI) between PFAA concentrations in maternal plasma and eczema during the first 24 months in the Hokkaido Study on Environment and Children's Health, Japan, 2003 Japan, -2009 . 
